Tags

Type your tag names separated by a space and hit enter

Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
Int J Urol. 2007 Feb; 14(2):118-22.IJ

Abstract

AIM

The efficacy and safety profiles of two alpha1-adrenoceptor antagonists, doxazosin gastrointestinal therapeutic system, a controlled-release formulation of doxazosin, and tamsulosin, were compared in Chinese men with confirmed benign prostatic hyperplasia.

METHODS

After a 2-week placebo run-in phase, 117 patients were randomized to daily treatment with doxazosin gastrointestinal therapeutic system (4 mg doxazosin) (n = 60) or 0.2 mg tamsulosin (n = 57) for 6 weeks with no titration of study medications. Efficacy was measured by the International Prostate Symptom Score, maximum urinary flow rate, postvoid residual urine volume, and quality-of-life score from the International Prostate Symptom Score. Adverse events were recorded.

RESULTS

Both drugs significantly improved the International Prostate Symptom Score (total, irritative subscore and obstructive subscore) and maximum urinary flow rate. Doxazosin gastrointestinal therapeutic system reduced postvoid residual urine volume significantly more than tamsulosin (-25 +/- 5 mL vs 2 +/- 5 mL, P = 0.041) in patients with residual volume >0 mL at baseline. Other differences between groups were not statistically significant.

CONCLUSIONS

The doxazosin gastrointestinal therapeutic system and tamsulosin were effective and well tolerated for the treatment of benign prostatic hyperplasia in Chinese men.

Authors+Show Affiliations

The Institute of Urology, Peking University, Beijing, China. zhaoyingxue01@yahoo.com.cnNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17302567

Citation

Xue, Zhaoying, et al. "Doxazosin Gastrointestinal Therapeutic System Versus Tamsulosin for the Treatment of Benign Prostatic Hyperplasia: a Study in Chinese Patients." International Journal of Urology : Official Journal of the Japanese Urological Association, vol. 14, no. 2, 2007, pp. 118-22.
Xue Z, Zhang Y, Ding Q, et al. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients. Int J Urol. 2007;14(2):118-22.
Xue, Z., Zhang, Y., Ding, Q., He, Z., Wang, J., & Xu, K. (2007). Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients. International Journal of Urology : Official Journal of the Japanese Urological Association, 14(2), 118-22.
Xue Z, et al. Doxazosin Gastrointestinal Therapeutic System Versus Tamsulosin for the Treatment of Benign Prostatic Hyperplasia: a Study in Chinese Patients. Int J Urol. 2007;14(2):118-22. PubMed PMID: 17302567.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients. AU - Xue,Zhaoying, AU - Zhang,Yuanfang, AU - Ding,Qiang, AU - He,Zhishong, AU - Wang,Jiangong, AU - Xu,Ke, PY - 2007/2/17/pubmed PY - 2007/5/5/medline PY - 2007/2/17/entrez SP - 118 EP - 22 JF - International journal of urology : official journal of the Japanese Urological Association JO - Int J Urol VL - 14 IS - 2 N2 - AIM: The efficacy and safety profiles of two alpha1-adrenoceptor antagonists, doxazosin gastrointestinal therapeutic system, a controlled-release formulation of doxazosin, and tamsulosin, were compared in Chinese men with confirmed benign prostatic hyperplasia. METHODS: After a 2-week placebo run-in phase, 117 patients were randomized to daily treatment with doxazosin gastrointestinal therapeutic system (4 mg doxazosin) (n = 60) or 0.2 mg tamsulosin (n = 57) for 6 weeks with no titration of study medications. Efficacy was measured by the International Prostate Symptom Score, maximum urinary flow rate, postvoid residual urine volume, and quality-of-life score from the International Prostate Symptom Score. Adverse events were recorded. RESULTS: Both drugs significantly improved the International Prostate Symptom Score (total, irritative subscore and obstructive subscore) and maximum urinary flow rate. Doxazosin gastrointestinal therapeutic system reduced postvoid residual urine volume significantly more than tamsulosin (-25 +/- 5 mL vs 2 +/- 5 mL, P = 0.041) in patients with residual volume >0 mL at baseline. Other differences between groups were not statistically significant. CONCLUSIONS: The doxazosin gastrointestinal therapeutic system and tamsulosin were effective and well tolerated for the treatment of benign prostatic hyperplasia in Chinese men. SN - 0919-8172 UR - https://www.unboundmedicine.com/medline/citation/17302567/Doxazosin_gastrointestinal_therapeutic_system_versus_tamsulosin_for_the_treatment_of_benign_prostatic_hyperplasia:_a_study_in_Chinese_patients_ L2 - https://doi.org/10.1111/j.1442-2042.2007.01502.x DB - PRIME DP - Unbound Medicine ER -